Angela Hartley Brodie

Angela Hartley Brodie's AcademicInfluence.com Rankings

Medical

#1150

World Rank

#1461

Historical Rank

Pharmacology

#250

World Rank

#295

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Angela Hartley Brodie Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Angela Hartley Brodie was a British biochemist who pioneered development of steroidal aromatase inhibitors in cancer research. Born in Lancashire , Brodie studied chemical pathology to a doctoral level in Sheffield and was awarded a fellowship sponsored by National Institutes of Health. After 17 years of working in Shrewsbury, Massachusetts on oral contraceptives with Harry Brodie, whom she married, she switched focus to the effects of the oestrogen-producing enzyme, aromatase, on breast cancer.

(See a Problem?)

Angela Hartley Brodie's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. (2009) (836)
Regulation of androgen receptor activity by tyrosine phosphorylation. (2006) (368)
The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. (1977) (365)
History of aromatase: saga of an important biological mediator and therapeutic target. (2009) (362)
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer (2007) (297)
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. (2005) (242)
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. (1987) (232)
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. (1986) (226)
Aromatase inhibitors in the treatment of breast cancer (1994) (225)
Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo (1981) (210)
4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER (1984) (195)
Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. (1996) (192)
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. (2003) (169)
Aromatase, aromatase inhibitors, and breast cancer (2011) (168)
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. (1994) (167)
Somatomedin-C-mediated potentiation of follicle-stimulating hormone-induced aromatase activity of cultured rat granulosa cells. (1985) (165)
The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. (1998) (155)
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. (2015) (154)
Aromatase and COX-2 expression in human breast cancers (2001) (153)
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. (2006) (150)
Obesity, Energy Balance, and Cancer: New Opportunities for Prevention (2012) (149)
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. (2005) (135)
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. (2011) (133)
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. (2004) (127)
4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer (1987) (123)
Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. (1996) (120)
An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. (1991) (120)
The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts (2004) (119)
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. (2005) (118)
Human testicular aromatase: immunocytochemical and biochemical studies. (1995) (118)
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. (2009) (116)
Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads. (1993) (116)
Studies on the mechanism of estrogen biosynthesis in the rat ovary--I. (1976) (112)
The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. (2005) (109)
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-Hydroxylase-C17,20-lyase (P45017α) : Potential agents for the treatment of prostate cancer (1998) (109)
Aromatase in the normal breast and breast cancer (1997) (108)
Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling (2010) (108)
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (2008) (104)
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors (2001) (99)
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer (2008) (98)
Aromatase inhibitors and their application in breast cancer treatment☆ (2000) (98)
Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione. (1980) (96)
17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha). (1997) (95)
Novel Membrane-associated Androgen Receptor Splice Variant Potentiates Proliferative and Survival Responses in Prostate Cancer Cells* (2011) (94)
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. (2005) (93)
Aromatase and its inhibitors (1999) (89)
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. (2008) (88)
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives. (1985) (87)
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications (1998) (87)
Aromatase in the human testis (1993) (83)
Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study. (1991) (83)
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. (1995) (82)
Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer (2010) (81)
Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction (1993) (77)
Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers (2011) (77)
Aromatase activity in cultured human genital skin fibroblasts. (1984) (76)
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. (2000) (75)
Aromatase inhibitors and their antitumor effects in model systems. (1999) (73)
Aromatase inhibition and its pharmacologic implications. (1985) (73)
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer (1999) (72)
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity (1998) (71)
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. (2003) (71)
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. (2011) (69)
Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor (2000) (68)
Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione. (1979) (68)
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. (2002) (67)
Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway Improves Response of Long-term Estrogen-Deprived Breast Cancer Xenografts to Antiestrogens (2007) (67)
Aromatase expression in the human male (2001) (67)
Aromatase and its inhibitors—an overview (1991) (65)
Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors. (1985) (64)
Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model (2011) (63)
17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response (2008) (61)
Inhibition of ovarian aromatase by prolactin in vivo. (1983) (60)
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro (2008) (60)
The effects of aromatase inhibitors and antiestrogens in the nude mouse model (1998) (59)
Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism. (1989) (57)
Aromatase inhibitors: basic and clinical studies. (1987) (55)
Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. (1999) (55)
Aromatase inhibitors and their use in controlling oestrogen-dependent processes. (1979) (54)
Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. (2006) (54)
Therapeutic observations in MCF-7 aromatase xenografts. (2005) (54)
Stopping treatment can reverse acquired resistance to letrozole. (2008) (54)
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors (1993) (53)
Model systems: Mechanisms involved in the loss of sensitivity to letrozole (2005) (51)
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. (2003) (51)
Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads. (1994) (50)
Aromatase expression in the human breast (2004) (50)
HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2 (2013) (49)
Aromatase inhibitors and their potential clinical significance. (1986) (49)
Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells* (2004) (48)
Challenges in the endocrine management of breast cancer. (2003) (47)
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. (2004) (47)
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR (2010) (47)
Immunocytochemical studies of aromatase in early and full-term human placental tissues: comparison with biochemical assays. (1989) (47)
Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. (1986) (47)
Aromatase inhibitors and the treatment of breast cancer. (1986) (47)
Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture (1997) (47)
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells (2011) (46)
Aromatease, its inhibitors and their use in breast cancer treatment (1993) (46)
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer (2012) (46)
Regulation of microsomal P450, redox partner proteins, and steroidogenesis in the developing testes of the neonatal pig. (2002) (44)
The effect of estrogen on aromatase and vascular endothelial growth factor messenger ribonucleic acid in the normal nonhuman primate mammary gland. (1999) (44)
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. (1998) (43)
Effect of 1,4,6-androstatriene-3,17-dione (ATD), 4-hydroxy-4-androstene-3,17-dione (4-OH-A) and 4-acetoxy-4-androstene-3,17-dione (4-Ac-A) on the 5 alpha-reduction of androgens in the rat prostate. (1986) (42)
Biochemical Assessment of Limits to Estrogen Synthesis in Porcine Follicles1 (2003) (41)
Aromatase inhibitors in breast cancer (2002) (39)
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth (2007) (39)
Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance (2011) (38)
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. (2016) (38)
Aromatase inhibitors, their pharmacology and application (1983) (38)
Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo (1999) (37)
Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. (1996) (37)
Comparison of biochemical aromatase activity with aromatase immunhistochemistry in human breast carcinomas (2004) (36)
Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model. (1982) (36)
Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo. (1982) (35)
Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase. (1996) (35)
Aromatase inhibitor development and hormone therapy: a perspective. (2003) (35)
Antifertility effects of an aromatase inhibitor, 1,4,6-androstatriene-3, 17-dione. (1979) (34)
Aromatase inhibitors prevent granulosa cell differentiation: an obligatory role for estrogens in luteinizing hormone receptor expression. (1985) (34)
Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors (1999) (34)
Sensitivity to the Aromatase Inhibitor Letrozole Is Prolonged After a “Break” in Treatment (2010) (34)
Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors (2011) (33)
Preclinical modeling of endocrine response and resistance (2008) (33)
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer (2014) (33)
Novel P45017α inhibitors: 17-(2′-oxazolyl)- and 17-(2′-thiazolyl)-androstene derivatives (2003) (33)
Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate Cancer–Bearing Severe Combined Immunodeficient Mice (2006) (33)
Effects of Exemestane and Tamoxifen in a Postmenopausal Breast Cancer Model (2004) (33)
Aromatase inhibitors and breast cancer (1996) (33)
Aromatase and breast cancer (2006) (31)
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. (2009) (31)
Metabolism of the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione by male rhesus monkeys. (1981) (31)
Neuroendocrine studies in hyperprolactinaemic male mice. (1987) (30)
Aromatase Inhibitors and Breast Cancer (2009) (30)
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens (2003) (29)
Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice (2006) (28)
Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17alpha-hydroxylase-C17,20-lyase inhibitors. (1999) (28)
Aromatase inhibitors and hormone-dependent cancers (1990) (28)
Aromatase inhibitors and breast cancer. (1996) (27)
Xenograft models for aromatase inhibitor studies (2007) (27)
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. (2006) (27)
Synthesis of deuterium- and tritium-labelled 4-hydroxyandrostene-3,17-dione, an aromatase inhibitor, and its metabolism in vitro and in vivo in the rat. (1982) (27)
Inhibition of androgen synthesis by 22‐hydroximino‐23,24‐bisnor‐4‐cholen‐3‐one (1995) (27)
Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB (2013) (27)
Role of FSH and oestradiol-17 beta in the development of meiotic competence in rat oocytes. (1983) (26)
Synthesis and in vitro activity of some epimeric 20α-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17α-hydroxylase/c 17,20 -lyase and 5α-reductase (1998) (26)
4-pregnene-3-one-20β-carboxaldehyde: A potent inhibitor of 17α-hydroxylase/C17,20-lyase and of 5α-reductase (1992) (26)
Inhibition of estrogen synthesis does not inhibit luteinizing hormone-induced ovulation. (1984) (25)
Aromatase and its inhibitors in breast cancer treatment — overview and perspective (2004) (25)
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. (2010) (25)
Recent advances in studies on estrogen biosynthesis (1979) (25)
Overview of recent development of aromatase inhibitors. (1982) (24)
Aromatase resistance mechanisms in model systems in vivo (2010) (24)
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model (2004) (24)
Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo (1999) (24)
Aromatase inhibitors III. Studies on the antifertility effect of 4-acetoxy-4-androstene-3,17-dione. (1978) (23)
In vitro and in vivo studies with aromatase inhibitor 4-hydroxyandrostenedione (1987) (23)
Anti-tumour effects and pharmacokinetic profile of 17-(5′ -isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis (2000) (23)
Aromatase, its inhibitors and their use in breast cancer treatment. (1993) (22)
Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors. (1981) (22)
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole (2010) (22)
Regulation of ovarian steroid biosynthesis by estrogen during proestrus in the rat. (1991) (22)
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. (1998) (21)
Aromatase inhibition and inactivation. (2001) (21)
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model (2015) (20)
Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione. (1988) (20)
Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids. (2000) (20)
Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells (2010) (19)
Effects of the Antiestrogen Tamoxifen and the Aromatase Inhibitor Letrozole on Serum Hormones and Bone Characteristics in a Preclinical Tumor Model for Breast Cancer (2004) (19)
Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. (1999) (18)
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease (2003) (18)
Androgen receptor inactivation contributes to antitumor efficacy of 17A-hydroxylase/17,20-lyase inhibitor (2008) (18)
Nuclear maturation of follicle-enclosed rat oocytes during inhibition of steriodogenesis (1983) (18)
Erratum: Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads (Journal of Clinical Endocrinology and Metabolism (1993) 77 (1616-1621)) (1994) (17)
Synthesis of novel 21-trifluoropregnane steroids: Inhibitors of 17α-hydroxylase/17,20-lyase (17α-lyase) (1997) (17)
Pseudoaromatase in circulating lymphocytes (1993) (17)
Synthesis of new steroidal isoxazoles: inhibitors of estrogen synthase. (1998) (17)
Effects of testosterone, estradiol, aromatase inhibitor, gonadotropin and prolactin on the response of mouse testes to acute gonadotropin stimulation. (1983) (17)
Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer (2015) (16)
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer (2004) (16)
Aromatase inhibitors and xenograft studies (2011) (16)
Applicability of the Intratumor Aromatase Preclinical Model to Predict Clinical Trial Results With Endocrine Therapy (2003) (15)
Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. (2009) (15)
Intratumoral aromatase model: The effects of letrozole (CGS 20267) (2004) (15)
Aromatase and other inhibitors in breast and prostatic cancer (1990) (15)
Effect of treatment with aromatase inhibitor 4-hydroxandrostenedione on the nonhuman primate menstrual cycle. (1989) (14)
The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. (1999) (14)
Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival (2010) (13)
Effect of selumetinib on the growth of anastrozole-resistant tumors (2013) (13)
Aromatase inhibitors as new endocrine therapy for breast cancer. (1988) (13)
mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. (2014) (12)
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer (2015) (12)
Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer (2002) (12)
P450arom gene expression in peripheral blood lymphocytes: Identification of a cryptic splice site for exon-1 afterEpstein–Barr virus transformation (1998) (11)
Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference (2008) (10)
The ErbB 3-binding protein Ebp 1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells (2005) (10)
Toremifene–atamestane; alone or in combination: Predictions from the preclinical intratumoral aromatase model (2008) (10)
Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. (2011) (10)
The influence of 4-hydroxy-4-androstene-3,17-dione on androgen metabolism and action in cultured human foreskin fibroblasts. (1987) (10)
Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. (2014) (9)
Advances in mechanisms of resistance to aromatase inhibitors (2014) (9)
The synthesis of N-aryl androsterone pyrazoles as aromatase inhibitors (1997) (9)
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. (1998) (9)
Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction (2012) (9)
Comparison of the effect of 4-hydroxy-4-androstene-3, 17-dione on aromatose activity in granulosa cells from preovulatory follicles of rats, rabbits, and humans (1985) (9)
The effect of alternating letrozole and tamoxifen in comparison to sequential treatment with each drug alone or in combination (2001) (8)
Effect of an aromatase inhibitor (4-acetoxy-4-androstene-3,17-dione) on the stimulatory action of luteinizing hormone on estradiol-17 beta synthesis by rat preovulatory follicles in vitro. (1981) (8)
The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat (1995) (7)
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. (2005) (7)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
Selective 19-hydroxylase inhibition by an aromatase inhibitor, 4-hydroxyandrostenedione. (1988) (6)
AROMATASE INHIBITORS. SYNTHESIS AND BIOLOGICAL ACTIVITY OF ANDROSTENEDIONE DERIVATIVES (1985) (6)
1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application. (1983) (6)
Inhibitors of 17α-Hydroxylase/17,20-Lyase (CYPl7): Potential Agents for the Treatment of Prostate Cancer (1999) (6)
Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice (2003) (5)
Breast cancer cells resistant to anti-hormone treatments retain sensitivity to Aminoflavone (NSC 686288) (2007) (5)
Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation (DOI:10.1016/j.ccr.2006.08.021) (2007) (5)
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. (2001) (5)
Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole (2006) (5)
The effect of tamoxifen on the pharmacokinetics of letrozole in female rats (2006) (4)
Abstract 5593: A combination of HDAC inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and low dose Doxorubicin causes regression of established xenografts of triple negative breast cancer (2010) (4)
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer (2011) (4)
Anti-HER 2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER 2-overexpressing breast tumor cells (2010) (4)
Abstract 1471: HER2 regulated miRNA expression in letrozole resistant breast cancer (2014) (4)
Combination of HDACi entinostat (SNDX-275) with letrozole provides control over tumor growth in MDA-MB-231 xenograft model. (2009) (4)
Steroidogenic enzyme inhibitors and hormone dependent cancer (2009) (4)
In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-androstenedione. (1987) (4)
4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase. (1992) (4)
Intrauterine growth retardation associated with precocious puberty and sertoli cell hyperplasia. (2010) (4)
Structure of 4-hydroxy-4-androstene-3,17-dione (1980) (3)
Predictions from a Preclinical Model (2003) (3)
Peritoneal Fluid Biochemistry in Infertile Women with Mild Pelvic Endometriosis (1986) (3)
Prepubertal gynaecomastia caused by medication or the aromatase excess syndrome (2004) (3)
Abstract 95: Inhibiiton of non-hypoxic HIF-1 expression in letrozole-resistant breast cancer cells reduces their cancer stem cell characteristics. (2013) (3)
Aromatase inhibitors: introduction and perspective. (1990) (3)
Effect of 4-Hydroxyandrostenedione on 19-hydroxylation of deoxycorticosterone in the golden syrian hamster (1988) (3)
Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives. (2003) (3)
Effect of 4-hydroxyandrostenedione on murine Leydig tumor cell steroidogenesis. (1991) (3)
Expression of ERα and Aromatase in MDA-MB-231 Tumors by HDAC Inhibitor Entinostat Leads to Growth Inhibition by Aromatase Inhibitor Letrozole. (2009) (3)
Abstract 2919: Effect of selumetinib and AZD8055 on the growth of anastrozole resistant tumors (2012) (3)
Gene expression changes during acquired resistance to tamoxifen and letrozole; a preclinical model of post-menopausal breast cancer (2005) (2)
Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib (2020) (2)
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA 1 and BRCA 2 Mutation Carriers (2012) (2)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
Synthesis of N‐Aryl‐Androsterone Pyrazoles as Aromatase Inhibitors. (1997) (2)
Preclinical modeling of endocrine response: a combination therapy approach with the ERβ agonist, diarryl propionitrile and letrozole restores sensitivity to letrozole-resistant breast cancer cells. (2009) (1)
Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model. (2013) (1)
Retraction: Aromatase Inhibitor–mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer (2018) (1)
David Kupfer and the Metabolism Connection: On Aromatase Inhibitors and Tamoxifen (2006) (1)
New Approaches to the Use of Endocrine Therapy in Breast Cancer (1984) (1)
Abstract 1062: Overexpression of miRNAs 181a and 222 play a role in triple negative breast cancer, and are targeted by entinostat (2016) (1)
Molecular studies of metastasis facilitated by a rapid autopsy program (2008) (1)
Gene expression changes during acquired resistance to tamoxifen; a preclinical model of post-menopausal breast cancer (2004) (1)
Aromatase Inhibitors for Breast Cancer Prevention (2016) (1)
Aromatase inhibitors and models for breast cancer (2008) (1)
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer (2014) (1)
Njar ( VN / 14-1 ) on Letrozole-Insensitive Breast Cancer Cells Effects of Novel Retinoic Acid Metabolism Blocking Agent (2006) (1)
2. Survival Impact of HER-2/Neu, Cox-2, Urokinase Plasminogen Activator (upa), Cytokeratin 17/5,6 and other Markers with Long-Term Outcome of Early Breast Cancer. Report from the British Columbia Tissue Micro-Array Project (BCTMAP) (2003) (1)
Treatment Strategies Using Letrozole and Tamoxifen in a Xenograft Model for Breast Cancer (2003) (1)
Advances in mechanisms of resistance to aromatase (2014) (0)
Gene expression changes during acquired resistance to tamoxifen; a preclinical model of post-menopausal breast cancer. (2004) (0)
Docetaxel Followedby Castration Improves Outcomes in LNCaPProstate Cancer ^ Bearing Severe Combined (2005) (0)
Abstract 2053: Mechanisms of resistance to palbociclib and aromatase inhibitors in hormone receptor positive breast cancer (2017) (0)
The Growth Factor GP88 (Progranulin) Confers Aromatase Inhibitor Resistance to Breast Cancer Cells. (2009) (0)
Abstract P5-19-05: Combination vorinostat and lapatinib reverses epithelial-mesenchymal transition, inhibits the cancer stem cell population of HER2+ breast cancer cells and is effective in heavily pretreated advanced tumors (2015) (0)
Abstract #4719: Nrf2 and drug resistance in breast cancer cells (2009) (0)
Aromatase Inhibitors and the Role of Hormonal Therapy in Breast Cancer (1999) (0)
123 GYNECOMASTIA IN THE PEUTZ-ZEGHERS SYNDROME IS CAUSED BY TESTICULRA TUMOR AROMATASE PRODUCTION (1988) (0)
92003469 Aromatase and its inhibitors - An overview (1992) (0)
Intraepithelial Neoplasia in Mouse Cancer and Its Overexpression Induces Prostate Tyrosine Kinase Etk / BMX Is Up-regulated in Human Prostate (2006) (0)
Abstract P3-05-06: A nude mouse model of diet-induced-obesity to study the mechanisms of resistance to aromatase inhibitor letrozole in MCF-7Ca xenografts (2015) (0)
Abstract P1-07-01: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin (2013) (0)
Abstract 1311: Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer. (2013) (0)
Basic studies and clinical findings with aromatase inhibitors (1994) (0)
Therapeutics , Targets , and Chemical Biology Dual IGF-1 R / InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer (2011) (0)
Endocrine Therapy in the Preoperative Setting and Strategies to Overcome Resistance (2011) (0)
Abstract 787: Involvement of HER2, HIF-1, and BCRP in cancer stem cell characteristics of letrozole-resistant breast cancer cells (2012) (0)
The Synthesis of Novel 7, 19-Bifunctional Androstenediones as Aromatase Inhibitors (2017) (0)
Preface (1993) (0)
Abstract PD5-2: Preclinical assessment of HDAC inhibitor entinostat combined with all trans retinoic acid (ATRA) in aromatase inhibitor resistant breast cancer (2013) (0)
Book Review (2007) (0)
The impact of dual inhibition on the androgen receptor and mTOR pathway cross talk in vitro and in vivo in prostate cancer models (2008) (0)
Tumor markers and their significance in the management of breast cancer : proceedings of a workshop held in Bethesda, Maryland, March 6, 1985 (1986) (0)
Androgen Metabolism Effects of 4-Hydroxyandrostenedione and Other Inhibitors on Lack of Evidence for Aromatase in Human Prostatic Tissues : Updated Version (2006) (0)
Cross talk between the PI3K/Akt/mTOR pathway and the androgen receptor in hormone dependent prostate cancer and its implication in the progression to androgen independence (2007) (0)
Abstract 5495: ALT NHEJ is a therapeutic target in hormone therapy resistant ER/PR/HER+ and ER/PR/HER- breast cancers (2011) (0)
ADVANCES WITH AROMATASE INHIBITORS (2013) (0)
Nucleophilic Vinylic “Addition‐Elimination” Substitution Reaction of 3. beta.‐Acetoxy‐17‐chloro‐16‐formylandrosta‐5,16‐diene: A Novel and General Route to 17‐Substituted Steroids. Part 1. Synthesis of Novel 17‐Azolyl‐δ16 Steroids; Inhibitors of 17α‐Hydroxylase/17, 20‐Lyase (17α‐Lyase). (1997) (0)
Abstract 3604: Effect of a new oral SERD AZD9496 on ER mediated signaling in xenograft model of postmenopausal breast cancer (2017) (0)
Abstract PD01-05: A Combination of HDAC Inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and Chemotherapy Drug(s) Causes Regression of Established Xenografts of Triple Negative Breast Cancer (2010) (0)
Hormones in normal and cancerous breast: basic and clinical applications (2012) (0)
The effect of aromatase inhibitor on hormone levels during the primate menstrual cycle (1987) (0)
Abstract OT3-2-11: A phase II study of letrozole and lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer (BC) (2013) (0)
The dual IGF-1 R / InsR inhibitor , BMS-754807 , demonstrates synergy in combination with hormonal agents in vitro and enhances in vivo activity in an estrogen-dependent breast cancer model (2011) (0)
Abstract 4596: Restoring hypoxia-inducible factor-1α in MCF-7 breast cancer cells in vitro by preventing the excessive degradation induced by high oxygen unmasks strong estradiol induction of vascular endothelial growth factor expression (2010) (0)
Abstract 1712: Androgen receptor splicing variants promote therapeutic resistance in prostate cancer (2010) (0)
Preface (2007) (0)
Abstract #2379: Hyaluronic acid_coated letrozole nanoparticles in targeting breast cancer enhances in vivo therapeutic activity and delay resistance (2009) (0)
A pharmaceutical composition comprising 3-hydroxy-beta-17- (1-H-benzimidazol-1-yl) androsta-5,16-diene (2006) (0)
Hormones and Cancer Reviewers (2011) (0)
Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival. (2011) (0)
PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. (2011) (0)
P1-02-02: Zoledronic Acid Reverses the Epithelial-Mesenchymal Transition While Inhibiting the Tumor Initiating Cell Population of Highly Tumorigenic Breast Cancer Cell Lines. (2011) (0)
Abstract 1314: HDAC inhibitor entinostat reverses letrozole resistance in MCF-7Ca xenografts through modulation of Her-2. (2013) (0)
Aromatase activity in cancer cells derived from a patient with recurrent breast cancer (1999) (0)
In Vivo Models of AI Resistance (2015) (0)
Abstract 1778: C-MYC plays a novel role in driving the error-prone double-strand break repair in triple negative breast cancers. (2013) (0)
Design, Synthesis and Evaluation of Growth Regulating SDF-1 Peptides on Breast Carcinoma Cells (2001) (0)
Abstract 621: Effect of diet-induced obesity on MCF-7Ca xenografts grown in ovariectomized athymic nude mice (2014) (0)
Abstract OT2-1-03: A pilot and phase II study of entinostat and anastrozole/tamoxifen in women with triple negative breast cancer (TNBC) to evaluate biomarkers and surrogates for response (2015) (0)
Synthesis of novel 21-trifluoropregnane steroids: inhibitors of 17 alpha-hydroxylase/17,20-lyase (17 alpha-lyase). (1997) (0)
Abstract 1472: MRP4 and PGT, members of the COX-2 pathway, may contribute to breast cancer progression (2011) (0)
Abstract 2295: Regulation of Her-2 in long-term letrozole resistant cells by HSP-90 (2011) (0)
Synthesis and in vitro activity of some epimeric 20 alpha-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17 alpha-hydroxylase/C17,20-lyase and 5 alpha-reductase. (1998) (0)
RAMBAs for Breast Cancer Prevention and Treatment (2009) (0)
Abstract P4-03-05: The Warburg Effect and RUNX2-Regulated Metabolic Switching in Breast Cancer: A New Therapeutic Target? (2010) (0)
Abstract P1-08-05: An association between obesity and more aggressive breast cancer subtype (2015) (0)
The impact of signal transduction pathways in a hormone dependent prostate cancer model (LNCaP cells). (2006) (0)
Abstract P2-09-10: A new oral SERD AZD9496 for treatment of hormone dependent postmenopausal breast cancer (2017) (0)
C-17 heteroaryl steroidal CYP17 inhibitors (2009) (0)
Abstract 520: Characterizing the AC1-exemestane resistant cell line to reveal the underlying mechanism of resistance to aromatase inhibitors in estrogen-dependent breast cancer . (2013) (0)
Abstract 3490: The effect of novel CYP17 inhibitor galeterone on gonadal and tumor progestogen and androgen levels in SCID mice bearing LNCaP prostate cancer xenografts (2016) (0)
Seribantumab, an Anti-ERBB3 Antibody, Delays theOnsetofResistanceandRestoresSensitivityto LetrozoleinanEstrogenReceptor-PositiveBreast (2015) (0)

This paper list is powered by the following services:

Other Resources About Angela Hartley Brodie

en.wikipedia.org

What Schools Are Affiliated With Angela Hartley Brodie?

Angela Hartley Brodie is affiliated with the following schools:

Angela Hartley Brodie's Academic­Influence.com Rankings